Study summary

A stem-cell transplant after induction kept more people free of lymphoma than further chemotherapy

MATRix/IELSG43 trial · 229 people randomized, phase 3 · Published August 2026, The Lancet

78%3-year progression-free with transplant, vs 51%

What was tested

High-dose chemotherapy with autologous stem-cell transplant (thiotepa and carmustine) against two cycles of non-myeloablative R-DeVIC chemotherapy, after four cycles of MATRix induction, in newly diagnosed PCNSL.

What they found

What it means

Establishes transplant consolidation as the preferred approach for fit patients up to about 70.

Lancet, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.